

How to assess pharmacogenomic tests for implementation in the NHS

Sonali Sanghvi¹, Robin Ferner², Andrew Scourfield³, Robert Urquhart¹, Sejal Amin¹, Aroon Hingorani³, and Reecha Sofat³

¹University College London Hospitals NHS Foundation Trust

²City Hospital

³University College London

January 26, 2023

Abstract

* Pharmacogenomic testing has the potential to target medicines more effectively towards those who will benefit and avoid use in individuals at risk of harm.

* Implementation of testing into routine practice across a healthcare system requires consideration of the evidence, clinical utility, cost-effectiveness, and operational requirements.

* A national approach to providing pharmacogenomic test recommendations and centralised commissioning will reduce inequity and duplication, but must be transparent and evidence based

Hosted file

BJCP Submission PGx Analysis Paper v2.docx available at <https://authorea.com/users/429308/articles/613971-how-to-assess-pharmacogenomic-tests-for-implementation-in-the-nhs>

Hosted file

Sanghvi_PGx_Figure 1.docx available at <https://authorea.com/users/429308/articles/613971-how-to-assess-pharmacogenomic-tests-for-implementation-in-the-nhs>

Hosted file

Sanghvi_PGx_Figure 2.docx available at <https://authorea.com/users/429308/articles/613971-how-to-assess-pharmacogenomic-tests-for-implementation-in-the-nhs>